BeOne announces 4 cancer programs for ESMO 2026

• BeOne Medicines announced new data presentations covering four investigational cancer treatments at ESMO 2026, scheduled for October 23–27 in Madrid.
• BeOne shares closed at US$369.06 on October 16, down 1.34%, before the announcement.
• The company will also present seven TEVIMBRA abstracts covering lung and gastrointestinal cancers, including Phase 3 findings involving ZIIHERA.

BeOne Medicines (NASDAQ:ONC) announced presentations covering four investigational cancer therapies and seven TEVIMBRA abstracts at ESMO 2026 in Madrid.

The presentations follow earlier 2026 clinical disclosures, including Phase 1 findings for BGB-B2033 and BGB-43395 at major oncology conferences.

The program includes BGB-B2033 for liver cancer, BG-C477 and BGB-58067 for selected advanced tumors, and BGB-43395 for breast cancer.

BeOne expects the October 23–27 congress to provide additional clinical evidence.

Seven TEVIMBRA abstracts include Phase 3 HERIZON-GEA-01 data evaluating treatment with ZIIHERA and chemotherapy for HER2-positive gastroesophageal cancer.

Earlier in 2026, BeOne reported Phase 3 HERIZON-GEA-01 survival findings, advanced its CDK4 inhibitor development and disclosed additional investigational gastrointestinal cancer data.